Kiora Pharmaceuticals (KPRX) Current Leases (2018 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Current Leases came in at $178217.0 in Q1 2026, up 149.07% YoY from $71554.0 in Q1 2025, and up 8.36% on a QoQ basis from $164461.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Current Leases (2018 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 9 years of Current Leases data on file, last reported at $178217.0 in Q1 2026.
- Quarterly Current Leases rose 149.07% year-over-year to $178217.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178217.0 (up 149.07% YoY) and the FY2025 annual result came in at $164461.0, up 604.18% from the prior year.
- Current Leases grew to $178217.0 in Q1 2026, from $164461.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $178217.0 in Q1 2026 to a low of $18725.0 in Q3 2023.
- A 5-year average of $88565.2 and a median of $73289.0 in 2023 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases soared 3588.25% — and 2023, when it slumped 85.76%.
- Tracing KPRX's Current Leases over 5 years: stood at $105782.0 in 2022, then slumped by 55.5% to $47069.0 in 2023, then slumped by 50.38% to $23355.0 in 2024, then surged by 604.18% to $164461.0 in 2025, then advanced by 8.36% to $178217.0 in 2026.
- The last three Current Leases figures came in at $178217.0 (Q1 2026), $164461.0 (Q4 2025), and $155926.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | 172,425.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 172,425.00 |
| Mar 31, 2026 | 178,217.00 |
| Dec 31, 2025 | 164,461.00 |
| Sep 30, 2025 | 155,926.00 |
| Jun 30, 2025 | 143,327.00 |
| Mar 31, 2025 | 71,554.00 |
| Dec 31, 2024 | 23,355.00 |
| Sep 30, 2024 | 33,447.00 |
| Jun 30, 2024 | 42,126.00 |
| Mar 31, 2024 | 47,851.00 |
| Dec 31, 2023 | 47,069.00 |
| Sep 30, 2023 | 18,725.00 |
| Jun 30, 2023 | 39,009.00 |
| Mar 31, 2023 | 73,289.00 |
| Dec 31, 2022 | 105,782.00 |
| Sep 30, 2022 | 131,482.00 |
| Jun 30, 2022 | 137,672.00 |
| Mar 31, 2022 | 92,317.00 |
| Dec 31, 2021 | 118,846.00 |
| Sep 30, 2021 | 144,742.00 |